Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.

You may also be interested in...



Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands

A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.

Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans

Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.

Beyond Herceptin: Kadcyla Carries Torch Across Lines Of HER2 Therapy

Genentech’s HER2 program director Dietmar Berger shares broader plans for Kadcyla (ado-trastuzumab emtansine) following its approval in second-line mBC, and expects Herceptin will continue to play a role in the long term.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel